可切除食管/食管胃交界腺癌和鳞状细胞癌患者新辅助治疗方案的最新进展
Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.
作者信息
Cox Samantha J, O'Cathail Sean M, Coles Bernadette, Crosby Tom, Mukherjee Somnath
机构信息
Cardiff University, Cardiff, CF10 3XQ, UK.
Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
出版信息
Curr Oncol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11912-017-0559-8.
Abstract
Survival outcomes following multimodal treatment of operable oesophageal and gastrooesophageal cancer remain disappointingly poor. Although an appreciation of the impact of both tumour location and histological subtype is now shaping the design of clinical trials, there has been a lack of consensus of the optimal neoadjuvant treatment strategy. This update article will review recent advances in the use of both neoadjuvant chemotherapy and chemoradiotherapy. The emerging role of PET imaging to direct appropriate neoadjuvant treatment regimens and the additive benefit of biological agents are also discussed.
摘要
可手术食管癌和胃食管癌多模式治疗后的生存结果仍然差强人意。尽管目前对肿瘤位置和组织学亚型影响的认识正在影响临床试验的设计，但对于最佳新辅助治疗策略仍缺乏共识。这篇更新文章将回顾新辅助化疗和放化疗使用方面的最新进展。还将讨论PET成像在指导合适的新辅助治疗方案方面的新兴作用以及生物制剂的附加益处。
相似文献
1
Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas.可切除食管/食管胃交界腺癌和鳞状细胞癌患者新辅助治疗方案的最新进展
Curr Oncol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11912-017-0559-8.
2
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.新辅助放化疗联合手术与单纯手术治疗食管或食管胃交界癌（CROSS）：一项随机对照临床试验的长期结果。
Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
3
Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.3D-CT 测量在评估食管癌放化疗早期疗效中的准确性和可重复性。
Eur J Surg Oncol. 2011 Dec;37(12):1064-71. doi: 10.1016/j.ejso.2011.09.004. Epub 2011 Sep 22.
4
Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer.可切除食管和胃食管交界处癌症的化疗和新型靶向治疗。
Best Pract Res Clin Gastroenterol. 2018 Oct-Dec;36-37:45-52. doi: 10.1016/j.bpg.2018.11.005. Epub 2018 Nov 22.
5
ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).ICORG 10 - 14：食管腺癌和食管胃交界腺癌国际研究（Neo - AEGIS）的新辅助试验
BMC Cancer. 2017 Jun 3;17(1):401. doi: 10.1186/s12885-017-3386-2.
6
7
Mucosal endocrine cell micronests and single endocrine cells following neo-adjuvant therapy for adenocarcinoma of the distal oesophagus and oesophagogastric junction.新辅助治疗后远端食管癌和食管胃交界腺癌的黏膜内分泌细胞微巢及单个内分泌细胞
J Clin Pathol. 2007 Nov;60(11):1284-9. doi: 10.1136/jcp.2007.047449. Epub 2007 Sep 24.
8
Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.可切除食管癌新辅助化疗或放化疗后的生存：更新的荟萃分析。
Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16.
9
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.一项关于新辅助化疗与新辅助放化疗治疗食管癌或胃食管交界癌的随机临床试验。
Ann Oncol. 2016 Apr;27(4):660-7. doi: 10.1093/annonc/mdw010. Epub 2016 Jan 17.
10
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?食管癌和食管胃交界癌新辅助化疗的症状反应：它们值得测量吗？
Clin Oncol (R Coll Radiol). 2006 May;18(4):345-50. doi: 10.1016/j.clon.2006.02.008.
引用本文的文献
1
Prognostic value of lymphovascular invasion in patients with esophageal squamous cell carcinoma.食管鳞状细胞癌患者淋巴管侵犯的预后价值
Ann Transl Med. 2019 Jun;7(12):256. doi: 10.21037/atm.2019.05.23.
2
Genetic Variants in EGFR/PLCE1 Pathway Are Associated with Prognosis of Esophageal Squamous Cell Carcinoma after Radical Resection.EGFR/PLCE1 通路中的遗传变异与根治性切除术后食管鳞癌的预后相关。
Curr Med Sci. 2019 Jun;39(3):385-390. doi: 10.1007/s11596-019-2047-x. Epub 2019 Jun 17.
3
Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer.放化疗不能改善食管鳞癌的预后。
J Surg Res. 2019 Apr;236:259-265. doi: 10.1016/j.jss.2018.11.052. Epub 2018 Dec 24.
4
Pan-endoscopic tumor length as the marker to predict response to neoadjuvant therapy for ESCC warrants additional investigation.全内镜下肿瘤长度作为预测食管鳞癌新辅助治疗反应的标志物值得进一步研究。
J Thorac Dis. 2018 Apr;10(Suppl 9):S1122-S1123. doi: 10.21037/jtd.2018.03.144.
本文引用的文献
1
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.新辅助放化疗联合手术与单纯手术治疗食管或食管胃交界癌（CROSS）：一项随机对照临床试验的长期结果。
Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.
2
Preoperative chemotherapy for resectable thoracic esophageal cancer.可切除胸段食管癌的术前化疗
Cochrane Database Syst Rev. 2015 May 19;2015(5):CD001556. doi: 10.1002/14651858.CD001556.pub3.
3
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.食管癌和胃食管交界部癌手术后的发病率和死亡率：新辅助化疗与新辅助放化疗的随机临床试验
Eur J Surg Oncol. 2015 Jul;41(7):920-6. doi: 10.1016/j.ejso.2015.03.226. Epub 2015 Apr 8.
4
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.S1联合奥沙利铂同步放化疗联合或不联合诱导化疗用于食管癌的随机2期试验
Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):489-96. doi: 10.1016/j.ijrobp.2014.11.019. Epub 2015 Jan 30.
5
Effects on heart function of neoadjuvant chemotherapy and chemoradiotherapy in patients with cancer in the esophagus or gastroesophageal junction - a prospective cohort pilot study within a randomized clinical trial.新辅助化疗和放化疗对食管癌或胃食管交界部癌患者心脏功能的影响——一项随机临床试验中的前瞻性队列先导研究
Radiat Oncol. 2015 Jan 13;10:16. doi: 10.1186/s13014-014-0310-7.
6
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.NeoFLOT：可切除胃食管交界处腺癌或胃腺癌围手术期化疗的多中心 II 期研究-具有良好的反应，主要在肠型肿瘤患者中。
Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25.
7
Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.前瞻性、开放、多中心 I/II 期试验，评估多西他赛和顺铂新辅助放化疗治疗食管癌的安全性和疗效。
Jpn J Clin Oncol. 2015 Feb;45(2):169-75. doi: 10.1093/jjco/hyu181. Epub 2014 Nov 21.
8
Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901.手术与放化疗后手术治疗Ⅰ期和Ⅱ期食管癌的比较：FFCD 9901 期随机对照Ⅲ期试验的最终分析。
J Clin Oncol. 2014 Aug 10;32(23):2416-22. doi: 10.1200/JCO.2013.53.6532. Epub 2014 Jun 30.
9
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.术前多西他赛、顺铂和氟尿嘧啶化疗治疗食管鳞癌的 II 期可行性研究。
Cancer Sci. 2013 Nov;104(11):1455-60. doi: 10.1111/cas.12274. Epub 2013 Oct 18.
10
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer.一项关于诱导化疗与无诱导化疗后行术前放化疗治疗食管癌的 II 期随机临床试验。
Ann Oncol. 2013 Nov;24(11):2844-9. doi: 10.1093/annonc/mdt339. Epub 2013 Aug 23.
Zotero 插件